Pharmac estimates the new approach will save approximately 3,700 infusion hours annually, easing pressure on oncology ...

Patients with chronic lymphocytic leukemia show higher risks for skin cancer, as well as skin cancer-specific metastasis and ...

CLL is linked to higher skin cancer risk and worse outcomes. Learn more about this large cohort study and its clinical ...

CLL is a slowgrowing blood cancer. While it can’t be cured, many people can live well for long periods with the right treatment. Pharmac estimates around 110 people each year will benefit from the new ...

A novel, fixed-duration drug combination - consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug - shows ...

“Pharmac also received feedback highlighting the need for ibrutinib on its own as an option for people who can’t use other available medicines. So, Pharmac will fund ibrutinib on its own as a ...

Serious infections occurred in 45.6% of patients and increased monthly hospital costs by AU$22,905, with elevated expenditure persisting for six months after the index infection. Episode-level excess ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

-New insights show Black, Hispanic, and Asian patients have more negative emotional experiences and outlooks with their chronic lymphocytic leukemia (CLL) diagnosis and treatment journeys-CLL is one ...

From May 1, people with chronic lymphocytic leukaemia will be able to access combination treatments of venetoclax with either ...

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that affects white blood cells called lymphocytes. There are many types of leukemia, and CLL is a common type in adults. This type of ...